Britain's GW Pharmaceuticals will have American clinical trials for Epidiolex, an investigational medication that uses cannabidiol, a marijuana extract. It could help children with rare forms of epilepsy such as Dravet and Lennox-Gastaut syndromes. (Seth McConnell, Denver Post file)

Clinical trials for marijuana seizure treatment ahead in N.Y.

ALBANY, N.Y. — New York state is partnering with a British company to hold clinical trials for marijuana-based medication for children who have seizures that are resistant to their medicine.

An agreement was signed Sunday between Gov. Andrew Cuomo’s administration and GW Pharmaceuticals. The state Health Department and the company will develop the framework for a clinical trial for a marijuana-based drug for people under the age of 18.

It will involve Epidiolex, an investigational medication that uses cannabidiol, a marijuana extract that doesn’t get users high. It could help children with rare forms of epilepsy such as Dravet and Lennox-Gastaut syndromes.

“Young New Yorkers battling these diseases deserve treatments that work for them, and by investigating the merits of cannabidiol we are pushing the boundaries of modern medicine and working to fundamentally improve the quality of life for those children,” Cuomo said Tuesday.

High-CBD marijuana: More coverage on Colorado-grown Charlotte’s Web, which has garnered national attention as parents and children flock to Colorado seeking treatment

Dravet syndrome is a rare genetic disorder typically untreatable by anti-epileptic drugs. It can be fatal. Lennox-Gastaut syndrome, another rare form of childhood-onset epilepsy, is characterized by different types of seizures multiple times a day and cognitive dysfunction. To be eligible for the trial, the children would have to show signs that their current medication is not working.

The Health Department is working on the framework for the protocol, which needs to be approved by the Food and Drug Administration before it is enacted. A state official with knowledge of the agreement told The Associated Press on Monday they expect FDA approval relatively quickly. The official spoke on condition of anonymity because the official was not authorized to speak publicly about the agreement.

In Colorado, the Charlotte’s Web strain of marijuana, which is high in cannabidiol content, has received international attention for its effect on children with severe seizures. It also is low in THC, the chemical responsible for most of marijuana’s psychological effects. The Realm of Caring, a nonprofit organization that produces the strain, currently has 206 people on its waiting list in the United States and separate waiting lists worldwide.

Health matters: Can hemp heal? Questions of science vs. semantics

The announcement of the agreement with GW Pharmaceuticals comes as medical marijuana legislation is being pushed into the forefront of New York state politics.

In January, Cuomo, a Democrat, proposed a pilot program to allow 20 hospitals statewide to administer medical marijuana to seriously ill patients under the Health Department’s guidelines.

And the Legislature is considering two medical marijuana bills. One called the Compassionate Care Act is making its way through the Republican-led Senate. It would allow patients with one of 20 serious illnesses to use the drug. The bill would bar anyone under the age of 21 from smoking marijuana but would allow the drug to be administered through a vaporizer, oil or something edible.

Another measure would prohibit smoking the drug in its entirety, but legalize medical marijuana use in vaporizer, oil or edible form for seriously ill patients.

Medical views: Why Drs. Gupta, Oz and Besser changed their stance on marijuana

This story was first published on